Palvella Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on the stock and has a $90.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors surrounding Palvella Therapeutics’ promising developments. The company has reported that their Phase 3 SELVA trial for QTORIN 3.9% rapamycin anhydrous gel, aimed at treating microcystic lymphatic malformations, is on track for data release in the first quarter of 2026. The trial has exceeded its enrollment target by over 25%, which suggests strong interest and potential efficacy in the treatment.
Additionally, the trial design has been optimized to reduce variability in clinician evaluations, which increases the likelihood of achieving statistically significant results. The efficacy observed in earlier phases of the trial suggests that the results could be even more favorable in the current, longer trial. Furthermore, the potential for QTORIN to become the first FDA-approved treatment specifically for microcystic lymphatic malformations could significantly boost prescriber interest and market adoption. These factors, combined with the FDA’s agreement on the trial design and endpoints, underpin Slutsky’s positive outlook and Buy rating for Palvella Therapeutics.
Slutsky covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Celldex, and DBV Technologies SA – American. According to TipRanks, Slutsky has an average return of 8.1% and a 34.81% success rate on recommended stocks.
In another report released today, JonesTrading also maintained a Buy rating on the stock with a $56.00 price target.